Clinical Trials
Study Title:
A Phase 3, Randomized, Double blind Study of Adjuvant Immunotherapy with Relatlimab and Nivolumab Fixed dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III IV Melanoma (RELATIVITY 098)
|
For more information about the trial above please contact the study team:
|